Page last updated: 2024-11-07

3-deoxy-manno-oct-2-ulopyranosonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-deoxy-manno-oct-2-ulopyranosonic acid (KDO) is a rare sugar that is a key component of the outer membrane of Gram-negative bacteria, where it is linked to lipid A. It is also found in some eukaryotic glycoconjugates. KDO is essential for bacterial viability and is a target for the development of new antibiotics. The biosynthesis of KDO involves a complex pathway that starts with the condensation of phosphoenolpyruvate and arabinose 5-phosphate. KDO is also involved in the biosynthesis of other important bacterial components, such as lipopolysaccharide (LPS) and capsular polysaccharides. KDO is a complex molecule that is difficult to synthesize. However, several synthetic methods have been developed, including those based on chemical and enzymatic approaches. KDO is an important target for the development of new antibiotics because it is essential for bacterial survival. Several studies have shown that KDO analogs can inhibit bacterial growth. KDO is also being investigated as a potential target for the development of new anti-inflammatory drugs.'
```

3-deoxy-manno-oct-2-ulopyranosonic acid: a component of cell wall lipopolysaccharide; artifacts in mass spectrometric analysis of Klebsiella pneumoniae; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-deoxy-D-manno-octulosonate : A carbohydrate acid anion obtained by deprotonation of the carboxy group of any 3-deoxy-D-manno-octulosonic acid [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID119228
CHEBI ID32817
SCHEMBL ID60922
MeSH IDM0332316

Synonyms (21)

Synonym
keto-3-deoxy-d-manno-octulosonic acid
CHEBI:32817
keto-3-deoxy-d-manno-oct-2-ulosonic acid
3-deoxy-d-manno-octulosonate
10149-14-1
3-deoxy-d-manno-2-octulosonate
C01187
3-deoxyoctulosonic acid
(4r,5r,6r,7r)-4,5,6,7,8-pentahydroxy-2-oxooctanoic acid
zwk96og89f ,
3-deoxy-manno-oct-2-ulopyranosonic acid
d-manno-2-octulosonic acid, 3-deoxy-
unii-zwk96og89f
kdo sugar acid
oligo-alpha(2,8)-3-deoxy-d-manno-2-octulosonic acid
2-keto-3-deoxy-d-manno-octonate
SCHEMBL60922
DTXSID80143949
Q27896886
Q1101052
(4r,5r,6r,7r)-2-oxo-4,5,6,7,8-pentahydroxyoctanoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3-deoxy-D-manno-octulosonic acidAn eight-membered ketoaldonic acid having D-manno configuration
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
CMP-3-deoxy-D-manno-octulosonate biosynthesis29

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.78)18.2507
2000's19 (52.78)29.6817
2010's15 (41.67)24.3611
2020's1 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index5.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (13.51%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (86.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]